Equities research analysts predict that Bio-Path Holdings, Inc. (NASDAQ:BPTH) will announce earnings of ($0.02) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Bio-Path Holdings’ earnings. Bio-Path Holdings also posted earnings per share of ($0.02) during the same quarter last year. The business is expected to report its next quarterly earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that Bio-Path Holdings will report full year earnings of ($0.08) per share for the current fiscal year. For the next financial year, analysts expect that the company will report earnings of ($0.11) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Bio-Path Holdings.

Bio-Path Holdings (NASDAQ:BPTH) last announced its earnings results on Thursday, August 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.01).

Several research firms have recently weighed in on BPTH. ValuEngine downgraded Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. HC Wainwright set a $5.00 price target on Bio-Path Holdings and gave the stock a “buy” rating in a research note on Friday, August 11th. Finally, Zacks Investment Research downgraded Bio-Path Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th.

Several hedge funds have recently bought and sold shares of the company. Sabby Management LLC grew its stake in shares of Bio-Path Holdings by 73.2% during the 2nd quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock worth $462,000 after acquiring an additional 503,488 shares during the period. HighTower Advisors LLC grew its stake in shares of Bio-Path Holdings by 0.3% during the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock worth $492,000 after acquiring an additional 4,000 shares during the period. Legal & General Group Plc grew its stake in shares of Bio-Path Holdings by 5,474.3% during the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after acquiring an additional 1,741,978 shares during the period. Tower Research Capital LLC TRC bought a new position in shares of Bio-Path Holdings during the 1st quarter worth $105,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Bio-Path Holdings by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after acquiring an additional 5,172 shares during the period. Institutional investors own 15.16% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/11/bio-path-holdings-inc-bpth-expected-to-post-earnings-of-0-02-per-share-2.html.

Shares of Bio-Path Holdings (BPTH) traded down 12.4602% during midday trading on Wednesday, hitting $0.4946. 1,053,643 shares of the stock were exchanged. The firm’s market capitalization is $49.49 million. The stock’s 50-day moving average price is $0.34 and its 200-day moving average price is $0.45. Bio-Path Holdings has a 1-year low of $0.25 and a 1-year high of $1.50.

Bio-Path Holdings Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Get a free copy of the Zacks research report on Bio-Path Holdings (BPTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.